Cargando…
MT30 Learnings from DTC Launch of a Digital Therapeutic for ADHD in Response to the COVID-19 FDA Policy for Digital Health Devices for the Treatment of Psychiatric Disorders
| Autor principal: | |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Published by Elsevier Inc.
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232794/ http://dx.doi.org/10.1016/j.jval.2022.04.1309 |
| _version_ | 1784735674723729408 |
|---|---|
| author | Palko, L |
| author_facet | Palko, L |
| author_sort | Palko, L |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9232794 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Published by Elsevier Inc. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-92327942022-06-27 MT30 Learnings from DTC Launch of a Digital Therapeutic for ADHD in Response to the COVID-19 FDA Policy for Digital Health Devices for the Treatment of Psychiatric Disorders Palko, L Value Health Article Published by Elsevier Inc. 2022-07 2022-06-25 /pmc/articles/PMC9232794/ http://dx.doi.org/10.1016/j.jval.2022.04.1309 Text en Copyright © 2022 Published by Elsevier Inc. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Article Palko, L MT30 Learnings from DTC Launch of a Digital Therapeutic for ADHD in Response to the COVID-19 FDA Policy for Digital Health Devices for the Treatment of Psychiatric Disorders |
| title | MT30 Learnings from DTC Launch of a Digital Therapeutic for ADHD in Response to the COVID-19 FDA Policy for Digital Health Devices for the Treatment of Psychiatric Disorders |
| title_full | MT30 Learnings from DTC Launch of a Digital Therapeutic for ADHD in Response to the COVID-19 FDA Policy for Digital Health Devices for the Treatment of Psychiatric Disorders |
| title_fullStr | MT30 Learnings from DTC Launch of a Digital Therapeutic for ADHD in Response to the COVID-19 FDA Policy for Digital Health Devices for the Treatment of Psychiatric Disorders |
| title_full_unstemmed | MT30 Learnings from DTC Launch of a Digital Therapeutic for ADHD in Response to the COVID-19 FDA Policy for Digital Health Devices for the Treatment of Psychiatric Disorders |
| title_short | MT30 Learnings from DTC Launch of a Digital Therapeutic for ADHD in Response to the COVID-19 FDA Policy for Digital Health Devices for the Treatment of Psychiatric Disorders |
| title_sort | mt30 learnings from dtc launch of a digital therapeutic for adhd in response to the covid-19 fda policy for digital health devices for the treatment of psychiatric disorders |
| topic | Article |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9232794/ http://dx.doi.org/10.1016/j.jval.2022.04.1309 |
| work_keys_str_mv | AT palkol mt30learningsfromdtclaunchofadigitaltherapeuticforadhdinresponsetothecovid19fdapolicyfordigitalhealthdevicesforthetreatmentofpsychiatricdisorders |